Caribou Biosciences (CRBU) Operating Income (2020 - 2026)
Caribou Biosciences (CRBU) reported Operating Income of -$26.3 million for Q1 2026, up 38.76% year-over-year from -$18.9 million in Q1 2025, and up 7.64% on a QoQ basis from -$28.5 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Operating Income data on file, last reported at -$26.3 million in Q1 2026.
- Quarterly Operating Income rose 38.76% year-over-year to -$26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$131.7 million (up 19.46% YoY) and the FY2025 annual result came in at -$148.3 million, up 10.97% from the prior year.
- Operating Income rose to -$26.3 million in Q1 2026 per CRBU's latest filing, from -$28.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$14.6 million in Q3 2023 and bottomed at -$47.6 million in Q2 2025.
- The 5-year median for Operating Income is -$31.1 million (2023), against an average of -$33.2 million.
- The widest annual swing landed in 2023, when Operating Income soared 44.86%; it then plunged 161.31% in 2024.
- Tracing CRBU's Operating Income over 5 years: stood at -$30.6 million in 2022, then retreated by 22.45% to -$37.4 million in 2023, then decreased by 3.83% to -$38.9 million in 2024, then rose by 26.81% to -$28.5 million in 2025, then climbed by 7.64% to -$26.3 million in 2026.
- Per Business Quant, the three latest CRBU Operating Income figures stand at -$26.3 million (Q1 2026), -$28.5 million (Q4 2025), and -$29.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -26.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.28 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Sep 30, 2025 | -29.40 Mn |
| Jun 30, 2025 | -47.58 Mn |
| Mar 31, 2025 | -42.91 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Sep 30, 2024 | -38.24 Mn |
| Jun 30, 2024 | -43.50 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Dec 31, 2023 | -37.44 Mn |
| Sep 30, 2023 | -14.63 Mn |
| Jun 30, 2023 | -32.87 Mn |
| Mar 31, 2023 | -31.12 Mn |
| Dec 31, 2022 | -30.58 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -28.43 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -20.41 Mn |
| Sep 30, 2021 | -18.62 Mn |
| Jun 30, 2021 | -15.96 Mn |
| Mar 31, 2021 | -13.18 Mn |
| Dec 31, 2020 | -15.21 Mn |
| Sep 30, 2020 | -8.23 Mn |
| Jun 30, 2020 | -2.26 Mn |
| Mar 31, 2020 | -10.43 Mn |